Mira Pavkovic
Pharma R&D
Wuppertal, NW, Germany
Wuppertal, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Molecular characterization of the uterotrophic assay: temporal gene expression changes in uterus and pituitary gland following ethinylestradiol.
Journal: Archives of toxicology
Published: April 26, 2026
Safety considerations for cereblon-recruiting targeted protein degraders.
Journal: Nature reviews. Drug discovery
Published: March 17, 2026
Single-Cell Resolution Drug Effects of Renin-Angiotensin-Aldosterone Blockade in ZSF1 Rat Diabetic Kidney Disease.
Journal: Journal of the American Society of Nephrology : JASN
Published: April 26, 2025
The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats.
Journal: International journal of molecular sciences
Published: July 14, 2023
Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution.
Journal: Cell reports. Medicine
Published: October 17, 2022
Targeted protein degraders: a call for collective action to advance safety assessment.
Journal: Nature reviews. Drug discovery
Published: March 24, 2022
Urinary miRNA Profiles in Chronic Kidney Injury-Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial Dysfunction.
Journal: Toxicological sciences : an official journal of the Society of Toxicology
Published: March 04, 2022
Free vitamin D is independently associated with systolic blood pressure in diabetic patients with impaired kidney function.
Journal: Clinical nephrology
Published: November 15, 2021
Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: August 09, 2021
Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
Journal: American journal of nephrology
Published: April 09, 2021
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
Journal: American journal of nephrology
Published: February 11, 2021
Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist.
Journal: Journal of cardiovascular pharmacology
Published: July 06, 2019
Last Updated: 09/26/2026